Appetite-suppressant drugs and valvular heart disease

New England Journal of Medicine

Volumn 340, Issue 6, 1999, Pages 476-

  Williamson, David F ^a,b   Yanovski, Susan Z ^a,b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; DEXFENFLURAMINE; FENFLURAMINE; PHENTERMINE;

CHEMICALLY INDUCED DISORDER; HUMAN; INCIDENCE; LETTER; METHODOLOGY; OBESITY; VALVULAR HEART DISEASE; FOOD AND DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL ANALYSIS; WEIGHT REDUCTION; PREVALENCE; RISK;

APPETITE DEPRESSANTS; DEXFENFLURAMINE; HEART VALVE DISEASES; HUMANS; INCIDENCE; OBESITY; RESEARCH DESIGN; DATA INTERPRETATION, STATISTICAL; FENFLURAMINE; PREVALENCE; RISK;

EID: 0033545378     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199902113400613     Document Type: Article

References (4)

1. Devereux RB. Appetite suppressants and valvular heart disease. N Engl J Med 1998;339:765-7.
2. Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE. A population-based study of appetite-suppressant drugs and the risk of car diac-valve regurgitation. N Engl J Med 1998;339:719-24.
3. Khan MA, Herzog CA, St Peter JV, et al. The prevalence of cardiac valvular insufficiency assessed by transthorack echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med 1998;339:713-8.
4. Weissman NJ, Tighe JF Jr, Gottdiener JS, Gwynne JT. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. N Engl J Med 1998;339:725-32.